Article Text

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
  1. W Katchamart1,2,
  2. J Trudeau3,
  3. V Phumethum1,
  4. C Bombardier4,5
  1. 1
    Rheumatology Division, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  2. 2
    Rheumatology Division, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  3. 3
    Hôspital Notre-Dame, Department of Rheumatology, Montreal, Canada
  4. 4
    Division of Rheumatology and Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
  5. 5
    Division of Clinical Decision Making and Health Care, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
  1. Dr C Bombardier, Institute for Work and Health, 481 University Avenue, Suite 800, Toronto, Ontario M5G 2E9, Canada; claire.bombardier{at}utoronto.ca

Abstract

Objective: To evaluate the efficacy and toxicity of methotrexate (MTX) monotherapy compared with MTX combination with non-biological disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis.

Method: A systematic review of randomised trials comparing MTX alone and in combination with other non-biological DMARDs was carried out. Trials were identified in Medline, EMBASE, the Cochrane Library and ACR/EULAR meeting abstracts. Primary outcomes were withdrawals for adverse events or lack of efficacy.

Results: A total of 19 trials (2025 patients) from 6938 citations were grouped by the type of patients randomised. Trials in DMARD naive patients showed no significant advantage of the MTX combination versus monotherapy; withdrawals for lack of efficacy or toxicity were similar in both groups (relative risk (RR) = 1.16; 95% CI 0.70 to 1.93). Trials in MTX or non-MTX DMARD inadequate responder patients also showed no difference in withdrawal rates between the MTX combo versus mono groups (RR = 0.86; 95% CI 0.49 to 1.51 and RR = 0.75; 95% CI 0.41 to 1.35), but in one study the specific combination of MTX with sulfasalazine and hydroxychloroquine showed a better efficacy/toxicity ratio than MTX alone with RR = 0.3 (95% CI 0.14 to 0.65). Adding leflunomide to MTX non-responders improved efficacy but increased the risk of gastrointestinal side effects and liver toxicity. Withdrawals for toxicity were most significant with ciclosporin and azathioprine combinations.

Conclusion: In DMARD naive patients the balance of efficacy/toxicity favours MTX monotherapy. In DMARD inadequate responders the evidence is inconclusive. Trials are needed that compare currently used MTX doses and combination therapies.

Statistics from Altmetric.com

Supplementary materials

Footnotes

  • Additional figures and appendixes are published online only at http://ard.bmj.com/content/vol68/issue7

  • Funding: This work was supported by Abbott with an unrestricted educational grant. Abbott had no role in the study design, literature search, data collection, data analysis, data interpretation or writing of this report.

  • Competing interests: CB holds a Canada Research Chair in knowledge transfer for musculoskeletal care.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles